Sulodexide for Secondary Prevention of Recurrent Venous Thromboembolism: A Systematic Review and Meta-Analysis.
Sulodexide for Secondary Prevention of Recurrent Venous Thromboembolism: A Systematic Review and Meta-Analysis.
复制标题
舒洛地昔用于复发性静脉血栓栓塞二级预防：系统评价和荟萃分析
DOI：
10.3389/fphar.2018.00876
复制
发表时间：
2018
影响因子：
5.6
通讯作者：
Qu L
中科院分区：
文献类型：
--
作者：
Jiang QJ;Bai J;Jin J;Shi J;Qu L
背景：静脉血栓栓塞患者在停止抗凝治疗后复发的风险很高。延长抗凝治疗，如传统抗凝剂，可降低复发风险，但与出血风险增加相关。舒洛地特是一种天然糖胺聚糖混合物，可预防复发性静脉血栓栓塞。然而，其临床疗效和安全性仍存在争议。方法：应用计算机检索Medline、EMBASE、科克伦图书馆、Web of Science及相关文献。纳入了报告舒洛地特对复发性静脉血栓栓塞的二级预防有效性和安全性的前瞻性对照研究。两名评审员独立提取了以下数据：第一作者、发表年份、研究设计、患者特征、干预数据、舒洛地特剂量、给药总持续时间、随访时间、疗效和安全性结局、不良反应和纳入研究的质量。主要疗效结局为复发性深静脉血栓形成（DVT）或肺栓塞。次要疗效结局包括远端或浅静脉血栓形成和非致死性或致死性心肌梗死、卒中和下肢急性缺血。安全性结局为可能的出血性事件。结果：本研究纳入了4项研究，涉及1，461例患者。荟萃分析显示，舒洛地特组复发性静脉血栓栓塞[RR 0.51，95%CI [0.35，0.74]，P = 0.0004]和浅静脉血栓形成[RR 0.41，95%CI [0.22，0.76]，P = 0.005]明显减少。舒洛地特安全性可靠。舒洛地特组的出血率为0.28%，对照组为1.60%，研究设计不影响这些结果。结论：舒洛地特与安慰剂相比，可显著降低抗凝治疗后VTE的复发率。
Background: Patients with venous thromboembolism have high risk of recurrence after discontinuation of anticoagulant treatment. Extended anticoagulation, such as traditional anticoagulants, can reduce the risk of recurrence but is associated with increased risk of hemorrhage. Sulodexide is a natural glycosaminoglycan mixture which can prevent recurrent venous thromboembolism. However, its clinical efficiency and safety still remain controversial. Methods: A systematic search in Medline, EMBASE, Cochrane Library, Web of Science and bibliographies of retrieved articles was performed. Prospective controlled studies reporting the efficacy and safety of sulodexide on the secondary prevention of recurrent venous thromboembolism were included. Two reviewers independently extracted the following data: first author, year of publication, study design, characteristics of patients, data of interventions, doses of sulodexide, overall duration of drug administration, time of follow-up, efficacy and safety outcomes, adverse effects, and the quality of the included studies. The primary efficacy outcomes were recurrent deep vein thrombosis (DVT) or pulmonary embolism. The secondary efficacy outcomes included distal or superficial vein thrombosis and nonfatal or fatal myocardial infarction, stroke, and acute ischemia of the lower limbs. Safety outcome was possible hemorrhagic episodes. Results: Four studies involving 1,461 patients were enrolled in this study. Meta-analysis showed that sulodexide significantly reduced the recurrent venous thromboembolism [RR 0.51, 95 % CI [0.35, 0.74], P = 0.0004] and superficial vein thrombosis in the sulodexide group [RR 0.41, 95% CI [0.22, 0.76], P = 0.005]. The safety of sulodexide was also reliable. The rate of bleeding was 0.28% in the sulodexide group and 1.60% in the control group, and design of study did not influence these results. Conclusions: Sulodexide could significantly reduce the recurrence of VTE after discontinuation of anticoagulation treatment as compared with placebo.
登录
查看更多内容
影响因子：
37.8
作者：
Andreozzi GM;Bignamini AA;Davì G;Palareti G;Matuška J;Holý M;Pawlaczyk-Gabriel K;Džupina A;Sokurenko GY;Didenko YP;Andrei LD;Lessiani G;Visonà A;SURVET Study Investigators
通讯作者：
SURVET Study Investigators
影响因子：
158.5
作者：
Becattini, Cecilia;Agnelli, Giancarlo;Prandoni, Paolo
通讯作者：
Prandoni, Paolo
DOI：
10.1007/bf02591420
发表时间：
1992-08-01
期刊：
INTERNATIONAL JOURNAL OF CLINICAL & LABORATORY RESEARCH
影响因子：
--
作者：
BARBANTI, M;GUIZZARDI, S;BABBINI, M
通讯作者：
BABBINI, M
影响因子：
39.2
作者：
Prandoni, P;Lensing, AWA;Girolami, A
通讯作者：
Girolami, A
影响因子：
2.3
作者：
MAURO, M;PALMIERI, GC;MILANI, MR
通讯作者：
MILANI, MR